Cargando…
O001 Reboxetine reduces obstructive sleep apnea severity: a randomized trial
INTRODUCTION: Noradrenergic and muscarinic processes are crucial for pharyngeal muscle control during sleep. Selective norepinephrine reuptake inhibitors (SNRIs) such as reboxetine combined with an antimuscarinic reduce obstructive sleep apnea (OSA) severity. The effects of reboxetine alone on OSA s...
Autores principales: | Altree, T, Aishah, A, Loffler, K, Grunstein, R, Eckert, D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108629/ http://dx.doi.org/10.1093/sleepadvances/zpab014.000 |
Ejemplares similares
-
P001 Safety, tolerability, and efficacy of 1 month of atomoxetine plus oxybutynin in obstructive sleep apnoea
por: Aishah, A, et al.
Publicado: (2021) -
P009 The effects of low-dose morphine on sleep and breathlessness in chronic obstructive pulmonary disease
por: Altree, T, et al.
Publicado: (2022) -
O013 The pathogenesis of obstructive sleep apnea in individuals with comorbid insomnia and obstructive sleep apnoea (COMISA)
por: Brooker, E, et al.
Publicado: (2021) -
O053 Obstructive sleep apnea is a distinct physiological phenotype in individuals with comorbid insomnia and sleep apnea (COMISA)
por: Brooker, E, et al.
Publicado: (2022) -
Impact of reboxetine plus oxybutynin treatment for obstructive sleep apnea on cardiovascular autonomic modulation
por: Perger, Elisa, et al.
Publicado: (2023)